NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
IB-Stim is FDA-cleared for specified abdominal pain conditions in patients ages 8 and older.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeurAxis (NRXS) announced new medical policy coverage from a national health insurer for approximately 26 million additional medical plan members.
The coverage spans multiple states and expands the national coverage footprint for PENFS, electrical stimulation of nerves in the ear, to over 147 million covered lives. IB-Stim is the company’s proprietary PENFS technology.
NeurAxis is hiring additional sales professionals following Craig Blanchard’s recent appointment as Chief Commercial Officer. The company anticipates further coverage gains from major insurers and believes broader coverage and an expanded commercial team position it for revenue growth and margin expansion.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNew insurer coverage adds approximately 26 million members, expanding PENFS coverage to over 147 million lives.
- Minor pointCommercial expansion includes active hiring of additional sales professionals to support physician adoption and patient access.
- Minor point. Forward-looking: it has not happened yet and may not happen.NeurAxis anticipates additional coverage gains from major insurers.
- Minor point. Forward-looking: it has not happened yet and may not happen.NeurAxis believes broader coverage and commercial expansion position it for revenue growth and margin expansion.
Negative
- None.
News Explained
NeurAxis announced new medical-policy coverage and described increased IB-Stim utilization and commercial results as work ahead, not as outcomes already reported from this coverage.
Details
Market move: NRXS +10.41% vs previous close. PENFS coverage expansion
On Oct 15, the day this news came out, the latest delayed price for NRXS is 10.41% above the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $7.21. Relative volume is exceptionally heavy at 34.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Additional covered lives
- Approximately 26 million medical plan members
- New national health insurer medical policy
- Total coverage footprint
- Over 147 million covered lives
- PENFS national coverage footprint
Historical Context
-
Prior insurer policy added approximately 18 million members and lifted PENFS coverage above 120 million lives.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
functional dyspepsia medical
off-label prescription drugs medical
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Total national coverage footprint for PENFS increases to over 147 million covered lives
CARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The coverage spans multiple states and represents approximately 26 million medical plan members.
NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including associated nausea symptoms in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain related to functional dyspepsia, a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.
“NeurAxis’ growth is accelerating as we continue to execute on our strategy to expand payer coverage and scale commercialization of IB-Stim,” said Brian Carrico, Chief Executive Officer of NeurAxis. “With our national coverage footprint now exceeding 147 million lives, we are strengthening our commercial organization to capitalize on these significant gains. The recent appointment of Craig Blanchard as Chief Commercial Officer is a key investment in our next phase of growth, and we are actively hiring additional sales professionals to drive physician adoption and help more patients access treatment under these new coverage policies.
“We anticipate additional coverage gains from major insurers and are expanding our sales capabilities to support both our growing coverage footprint and the opportunities ahead,” Carrico continued. “Our focus is on execution and turning payer coverage milestones into increased utilization of IB-Stim and meaningful commercial results. Backed by a solid balance sheet, we believe the combination of broader insurance coverage, dedicated commercial leadership and an expanded sales team positions NeurAxis for significant revenue growth and margin expansion.”
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.
For important RED information, including indications, precautions, and contraindications, visit: https://red4constipation.com/information/
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many additional members does NeurAxis’ new PENFS coverage reach?
The new medical policy coverage reaches approximately 26 million medical plan members across multiple states. It comes from a national health insurer and brings the total national PENFS coverage footprint to over 147 million covered lives.
What conditions and ages is NeurAxis’ IB-Stim FDA-cleared to treat?
IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia, including nausea symptoms associated with functional dyspepsia, in patients 8 years and older.